Ole Lemming

1.4k total citations
27 papers, 1.1k citations indexed

About

Ole Lemming is a scholar working on Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, Ole Lemming has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 14 papers in Pharmacology and 6 papers in Experimental and Cognitive Psychology. Recurrent topics in Ole Lemming's work include Treatment of Major Depression (12 papers), Schizophrenia research and treatment (9 papers) and Electroconvulsive Therapy Studies (6 papers). Ole Lemming is often cited by papers focused on Treatment of Major Depression (12 papers), Schizophrenia research and treatment (9 papers) and Electroconvulsive Therapy Studies (6 papers). Ole Lemming collaborates with scholars based in Denmark, United Kingdom and United States. Ole Lemming's co-authors include Alan Wade, Dan J. Stein, Siegfried Kasper, Stuart Montgomery, Per Bech, David Wilkinson, José Luís Molinuevo, Anne‐Liis von Knorring, Cornelius Katona and Philip Gorwood and has published in prestigious journals such as Journal of the American Academy of Child & Adolescent Psychiatry, Schizophrenia Research and Acta Psychiatrica Scandinavica.

In The Last Decade

Ole Lemming

27 papers receiving 993 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ole Lemming Denmark	16	486	464	342	301	165	27	1.1k
P.M.J. Haffmans Netherlands	20	341 0.7×	455 1.0×	359 1.0×	221 0.7×	203 1.2×	44	1.2k
Rajinder Judge United States	15	421 0.9×	333 0.7×	354 1.0×	358 1.2×	107 0.6×	17	1.1k
Maurizio Fava United States	13	536 1.1×	461 1.0×	414 1.2×	165 0.5×	227 1.4×	17	1.2k
Shirin Khan United States	13	690 1.4×	577 1.2×	367 1.1×	442 1.5×	316 1.9×	19	1.5k
Shamsah B. Sonawalla United States	19	341 0.7×	364 0.8×	245 0.7×	278 0.9×	104 0.6×	30	1.1k
Maximilian Pilhatsch Germany	20	329 0.7×	319 0.7×	138 0.4×	236 0.8×	211 1.3×	54	1.3k
Diane McIntosh Canada	10	743 1.5×	496 1.1×	419 1.2×	297 1.0×	133 0.8×	18	1.5k
Abigail Ortiz Canada	17	443 0.9×	461 1.0×	256 0.7×	233 0.8×	133 0.8×	56	1.2k
Wolfram Bender Germany	16	418 0.9×	408 0.9×	256 0.7×	220 0.7×	172 1.0×	30	952
Shane McInerney Canada	15	537 1.1×	542 1.2×	291 0.9×	296 1.0×	217 1.3×	35	1.3k

Countries citing papers authored by Ole Lemming

Since Specialization

Citations

This map shows the geographic impact of Ole Lemming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ole Lemming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ole Lemming more than expected).

Fields of papers citing papers by Ole Lemming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ole Lemming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ole Lemming. The network helps show where Ole Lemming may publish in the future.

Co-authorship network of co-authors of Ole Lemming

This figure shows the co-authorship network connecting the top 25 collaborators of Ole Lemming. A scholar is included among the top collaborators of Ole Lemming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ole Lemming. Ole Lemming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meyer‐Lindenberg, Andreas, Jacob Nielsen, Pedro Such, et al.. (2022). A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia. European Neuropsychopharmacology. 61. 4–14. 9 indexed citations

Kane, John M., Bruce J. Kinon, Carlos Forray, et al.. (2022). Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension. Schizophrenia Research. 248. 271–278. 10 indexed citations

Findling, Robert L., Adelaide S. Robb, Melissa P. DelBello, et al.. (2017). A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology. 28(1). 47–54. 15 indexed citations

Findling, Robert L., Adelaide S. Robb, Melissa P. DelBello, et al.. (2017). Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. Journal of Child and Adolescent Psychopharmacology. 27(6). 526–534. 15 indexed citations

Suppes, Trisha, Jonas Eberhard, Ole Lemming, Allan H. Young, & Roger S. McIntyre. (2017). Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. International Journal of Bipolar Disorders. 5(1). 36–36. 22 indexed citations

Findling, Robert L., Adelaide S. Robb, Melissa P. DelBello, et al.. (2016). 4.62 A SIX-MONTH OPEN-LABEL EXTENSION STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS. Journal of the American Academy of Child & Adolescent Psychiatry. 55(10). S183–S183. 1 indexed citations

Herrmann, Nathan, Serge Gauthier, Neli Boneva, & Ole Lemming. (2013). A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. International Psychogeriatrics. 25(6). 919–927. 43 indexed citations

Atri, Alireza, José Luís Molinuevo, Ole Lemming, et al.. (2013). Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimer s Research & Therapy. 5(1). 6–6. 95 indexed citations

Wilkinson, David, et al.. (2012). Memantine and Brain Atrophy in Alzheimer's Disease: A 1-Year Randomized Controlled Trial. Journal of Alzheimer s Disease. 29(2). 459–469. 34 indexed citations

10.

Hale, Anthony S., et al.. (2012). Sertindole in the long-term treatment of schizophrenia. International Clinical Psychopharmacology. 27(4). 231–237. 6 indexed citations

11.

Riepe, Matthias W., et al.. (2011). Measuring Therapeutic Efficacy in Patients with Alzheimer’s Disease: Role of Instruments. Dementia and Geriatric Cognitive Disorders. 31(3). 233–238. 7 indexed citations

12.

Riepe, Matthias W., et al.. (2011). P4‐237: Efficiency of memantine ‐ a meta‐analysis of non‐interventional studies in the treatment of Alzheimer's disease. Alzheimer s & Dementia. 7(4S_Part_23). 1 indexed citations

13.

Fineberg, Naomi, et al.. (2007). Escitalopram prevents relapse of obsessive-compulsive disorder. European Neuropsychopharmacology. 17(6-7). 430–439. 56 indexed citations

14.

Gorwood, Philip, Emmanuelle Weiller, Ole Lemming, & Cornelius Katona. (2007). Escitalopram Prevents Relapse in Older Patients With Major Depressive Disorder. American Journal of Geriatric Psychiatry. 15(7). 581–593. 69 indexed citations

15.

Kasper, Siegfried, Ole Lemming, & Hans de Swart. (2006). Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients. Neuropsychobiology. 54(3). 152–159. 16 indexed citations

16.

Knorring, Anne‐Liis von, Gunilla Olsson, Per Hove Thomsen, Ole Lemming, & Agnes Hultén. (2006). A Randomized, Double-blind, Placebo-controlled Study of Citalopram in Adolescents With Major Depressive Disorder. Journal of Clinical Psychopharmacology. 26(3). 311–315. 83 indexed citations

17.

Wade, Alan, et al.. (2002). Escitalopram 10???mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology. 17(3). 95–102. 196 indexed citations

18.

Montgomery, Stuart, et al.. (2001). Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology. 16(2). 75–86. 136 indexed citations

19.

Bougerol, Thierry, et al.. (1997). Citalopram and Fluoxetine in Major Depression. Clinical Drug Investigation. 14(2). 77–89. 25 indexed citations

20.

Patris, Michel, et al.. (1996). Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. International Clinical Psychopharmacology. 11(2). 129–136. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact